PD-1
11 drugsProgrammed Cell Death Protein 1
Predictive biomarker for patient selection in 31 indications
Understanding PD-1
What it means: PD-1 is an immune checkpoint receptor on T cells. When bound by PD-L1, it suppresses T cell activity, allowing cancer to evade immune attack.
Why it matters: Anti-PD-1 antibodies (pembrolizumab, nivolumab) block this interaction, reactivating T cells to attack tumors. Used across many cancer types.
Testing: PD-1 status is typically assessed via PD-L1 expression testing on tumor tissue (IHC). PD-L1 levels help predict response.
11
Approved Drugs
31
Indications
8
Companies
Search PD-1 Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PD-1
| Drug | Company | Therapeutic Area |
|---|---|---|
| JEMPERLI | GSK | Oncology |
| KEYTRUDA | Merck | Oncology |
| KEYTRUDA QLEX | Merck | Oncology |
| LIBTAYO | Regeneron | Oncology |
| LOQTORZI | COHERUS BIOSCIENCES INC | Oncology |
| OPDIVO | Bristol-Myers Squibb | Oncology |
| OPDIVO QVANTIG | Bristol-Myers Squibb | Oncology |
| OPDUALAG | Bristol-Myers Squibb | Oncology |
| PENPULIMAB-KCQX | AKESO BIOPHARMA | Oncology |
| TEVIMBRA | BEIGENE | Oncology |
| ZYNYZ | INCYTE CORP | Oncology |
Indications
Nasopharyngeal Carcinoma Melanoma Non-Small Cell Lung Cancer Squamous Cell Carcinoma of the Anal Canal Merkel Cell Carcinoma Renal Cell Carcinoma Classical Hodgkin Lymphoma Head and Neck Cancer Urothelial Carcinoma Colorectal Cancer Hepatocellular Carcinoma Esophageal Cancer Gastric Cancer Mesothelioma Esophageal Squamous Cell Carcinoma Gastroesophageal Junction Adenocarcinoma Metastatic cutaneous squamous cell carcinoma Locally advanced cutaneous squamous cell carcinoma Adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation Locally advanced basal cell carcinoma Metastatic basal cell carcinoma First-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with platinum-based chemotherapy First-line monotherapy for locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression (TPS ≥50%) Endometrial Cancer Solid Tumors Unresectable melanoma Metastatic melanoma Cervical Cancer Cutaneous Squamous Cell Carcinoma Triple-Negative Breast Cancer Biliary Tract Cancer